American Journal of Epidemiology Vol. 153, No. 9 : 912-920
Copyright © 2001 by The Johns Hopkins University School of Hygiene and Public Health
ORIGINAL CONTRIBUTIONS |
Incidence of Herpes Simplex Virus Type 2 Infection in the United States
1 Office of Surveillance, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA.
2 Division of STD Prevention, National Center for HIV, STD, and Tuberculosis Prevention, Centers for Disease Control and Prevention, Atlanta, GA.
3 Department of Pediatrics, Emory University School of Medicine, Atlanta, GA.
4 Division of Health Examination Statistics, National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, MD.
Between the time that two large, national surveys were conducted, the Second National Health and Nutrition Examination Survey (1976–1980) and the Third National Health and Nutrition Examination Survey (1988–1994), prevalence of herpes simplex virus type 2 (HSV-2) infection in the United States increased by 30%. From these survey data, the authors estimated the incidence of HSV-2 infection in the civilian, noninstitutionalized population aged 
12 years by means of a mathematical model that allowed overall incidence to increase linearly with time but required the shape of the age-specific incidence curve to remain constant. From 1970 to 1985, annual incidence of HSV-2 infection in HSV-2-seronegative persons increased by 82%, from 4.6 per 1,000 (95% confidence interval: 4.2, 5.0) to 8.4 per 1,000 (95% confidence interval: 7.7, 9.1). Incidence in 1985 was higher in women than in men (9.9 vs. 6.9 per 1,000), higher in Blacks than in Whites (20.4 vs. 6.3 per 1,000), and highest in the group aged 20–29 years (14.6 and 22.5 per 1,000 in men and women, respectively). Thus, by 1985, approximately 1,640,000±150,000 persons (730,000 men and 910,000 women) were being infected annually with HSV-2.
herpes simplex; herpesvirus 2, human; incidence; mathematical computing; models, theoretical; prevalence; serologic tests
Abbreviations: CI, confidence interval; HSV-1 (2), herpes simplex virus type 1 (2); NHANES II (III), Second (Third) National Health and Nutrition Examination Survey.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M O Ng'ayo, E Bukusi, R A Morrow, A Rowhani-Rahbar, B A Obare, D Friedrich, and K K Holmes Sexual and demographic determinants for herpes simplex virus type 2 among fishermen along Lake Victoria, Kenya Sex Transm Inf, April 1, 2008; 84(2): 140 - 142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Thapa, W. A. Kuziel, and D. J. J. Carr Susceptibility of CCR5-Deficient Mice to Genital Herpes Simplex Virus Type 2 Is Linked to NK Cell Mobilization J. Virol., April 15, 2007; 81(8): 3704 - 3713. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N Dickson, T van Roode, P Herbison, J Taylor, A Cunningham, and C Paul Risk of herpes simplex virus type 2 acquisition increases over early adulthood: evidence from a cohort study Sex Transm Inf, April 1, 2007; 83(2): 87 - 90. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R G Pebody, N Andrews, D Brown, R Gopal, H de Melker, G Francois, N Gatcheva, W Hellenbrand, S Jokinen, I Klavs, et al. The seroepidemiology of herpes simplex virus type 1 and 2 in Europe Sex Transm Inf, June 1, 2004; 80(3): 185 - 191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Aurelian Herpes Simplex Virus Type 2 Vaccines: New Ground for Optimism? Clin. Vaccine Immunol., May 1, 2004; 11(3): 437 - 445. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Q. Wales, C. C. Smith, M. Wachsman, G. Calton, and L. Aurelian Performance and Use of a Ribonucleotide Reductase Herpes Simplex Virus Type-Specific Serological Assay Clin. Vaccine Immunol., January 1, 2004; 11(1): 42 - 49. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Corey, A. Wald, R. Patel, S. L. Sacks, S. K. Tyring, T. Warren, J. M. Douglas Jr., J. Paavonen, R. A. Morrow, K. R. Beutner, et al. Once-Daily Valacyclovir to Reduce the Risk of Transmission of Genital Herpes N. Engl. J. Med., January 1, 2004; 350(1): 11 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Herbst and R. B. Pyles Immunostimulatory CpG treatment for genital HSV-2 infections J. Antimicrob. Chemother., December 1, 2003; 52(6): 887 - 889. [Full Text] [PDF]
|
|
|
|
 |
|
 Z. A. Brown, A. Wald, R. A. Morrow, S. Selke, J. Zeh, and L. Corey Effect of Serologic Status and Cesarean Delivery on Transmission Rates of Herpes Simplex Virus From Mother to Infant JAMA, January 8, 2003; 289(2): 203 - 209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Howard, J. W. Sellors, D. Jang, N. J. Robinson, M. Fearon, J. Kaczorowski, and M. Chernesky Regional Distribution of Antibodies to Herpes Simplex Virus Type 1 (HSV-1) and HSV-2 in Men and Women in Ontario, Canada J. Clin. Microbiol., January 1, 2003; 41(1): 84 - 89. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Chutkowski, B. Olson, A. McDonough, J. Mahoney, and J. J. McSharry Use of a Single Monoclonal Antibody To Determine the Susceptibilities of Herpes Simplex Virus Type 1 and Type 2 Clinical Isolates to Acyclovir Clin. Vaccine Immunol., November 1, 2002; 9(6): 1379 - 1381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Armstrong and B. P. Bell Hepatitis A Virus Infections in the United States: Model-Based Estimates and Implications for Childhood Immunization Pediatrics, May 1, 2002; 109(5): 839 - 845. [Abstract] [Full Text] [PDF]
|
|